Arrowhead Pharma Stock Price, News & Analysis

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced the closure of its exclusive license agreement with GlaxoSmithKline (LSE/NYSE: GSK), initially revealed on November 22, 2021. The transaction's closing was contingent upon meeting customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. This milestone marks a significant step in Arrowhead's collaboration with GSK, potentially impacting its product development and market position.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will hold a webcast and conference call on February 2, 2022, at 4:30 p.m. ET to discuss its financial results for the first quarter of fiscal 2022, ending December 31, 2021. Interested investors can access the live audio on the company’s website. A replay will be available afterward for 90 days. Arrowhead focuses on developing RNAi-based therapeutics, targeting diseases by silencing specific genes through its innovative RNA chemistries and delivery methods.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated the Phase 3 PALISADE study to evaluate the efficacy and safety of ARO-APOC3 in patients with familial chylomicronemia syndrome (FCS). ARO-APOC3, an RNA interference therapeutic, aims to inhibit apolipoprotein C3 production, critical for triglyceride metabolism. The study will involve approximately 60 participants and assess changes in triglyceride levels over 56 weeks. Previous studies indicated a significant triglyceride reduction of up to 91%. The company is also collaborating with Ambry Genetics for genetic testing for at-risk patients.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has acquired 13 acres in Verona Technology Park, Wisconsin, where it plans to build a drug manufacturing facility (140,000 sq. ft.) and a laboratory/office space (115,000 sq. ft.). The investment, estimated between $200 million and $250 million, aims to create about 250 jobs. Construction is set to begin in Q1 2022, with lab completion expected in Q1 2023 and manufacturing in Q4 2023. This expansion underscores Arrowhead’s commitment to the Wisconsin biotech ecosystem and supports its growing pipeline of RNAi medicines.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced the approval of inducement grants for 24 new employees by its Compensation Committee on December 14, 2021. The grants, totaling up to 87,000 restricted stock units, are meant to incentivize employment and are outside the company’s stockholder-approved equity incentive plans. These units will vest annually over four years, reflecting the company's commitment to attracting talent in its mission to develop innovative RNA interference therapies for intractable diseases.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced its participation in two upcoming industry events. On December 2, 2021, Chris Anzalone, Ph.D., president and CEO, will engage in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference at 1:00 p.m. ET. Following this, December 3, 2021, James Hamilton, MD, MBA, will partake in a panel discussion at the 18th Global Cardiovascular Clinical Trialists Forum, focused on Hypertriglyceridemia Trials. Presentation materials and live webcasts will be available on the company's website.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported a revenue of $138.3 million for the fiscal year ending September 30, 2021, up from $88.0 million in 2020. Net loss increased to $140.8 million, or $1.36 per diluted share, compared to $84.6 million, or $0.84 per share, last year. Operating expenses rose significantly to $287.3 million, led by R&D costs of $206.3 million. Cash and cash equivalents totaled $184.4 million, with total assets at $710.1 million. The company also announced a collaboration with GSK for ARO-HSD and received Breakthrough Therapy designation for ARO-AAT.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has finalized an exclusive license agreement with GlaxoSmithKline (LSE/NYSE: GSK) for ARO-HSD, a therapeutic for nonalcoholic steatohepatitis (NASH). Arrowhead will receive a $120 million upfront payment and could earn up to $1.1 billion in additional milestone payments and royalties. The agreement allows GSK to develop ARO-HSD globally, except in Greater China, where Arrowhead retains rights. The transaction is expected to close in Q1 2022, pending customary conditions.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a collaboration with Janssen Pharmaceuticals on the investigational compound JNJ-75220795, currently in a Phase 1 clinical study. This siRNA therapeutic targets the reduction of PNPLA3 expression in the liver, aimed at treating non-alcoholic steatohepatitis (NASH). The collaboration began in October 2018 and leverages Arrowhead's TRIM platform, demonstrating the potential to address significant liver disease by targeting genetic factors associated with fat accumulation.